To view this content, JavaScript must be enabled,
and you need the latest version of the Adobe Flash Player.
We are no longer accepting applications for the A-2012 review period. The application period will re-open on April 1, 2012
Please note Areas of Interest will be available on March 22, 2012 for Request Cyle B.
Learn more about our quarterly review process for MS Neurology HCP and Patient Educational Grants
please click here.
Now accepting applications with event dates on or after
Effective April 1st all NOFA proposals will be incorporated into the MS Neurology Request process. Please reference Educational Grants for quarterly updates on Areas of Interest.
2012 Fellowship application period is now closed.
As a global leader in Neurology, Biogen Idec is committed to bringing life-saving and life-changing therapies to patients with serious neurological diseases, such as amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, and Parkinson's disease, where there is a tremendous need for new treatments.
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients worldwide benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.
Through its Medical Education Program, Biogen Idec strives to support independent, rigorous, and timely educational programs aimed at improving patient care and health care provider performance.
